comparemela.com

Latest Breaking News On - Michiels van der heijden - Page 1 : comparemela.com

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Perez valderramaMichiels vanBristol myers squibbAstellas pharmaGilead sciencesCancers symposiumDer heijdenEnfortumab vedotinAsco guGenitourinary cancers symposiumEv 302Keynote a39 trialMichiels van der heijdenNetherlands cancer instituteSubgroup analysisUrothelial carcinoma

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Noord hollandMichiels vanNetherlands cancer instituteConcurrent frontline nivolumab and gemcitabine cisplatinUrothelial carcinomaCheckmate 901 studyMichiels van der heijden

vimarsana © 2020. All Rights Reserved.